Eloralintide
Research highlights
- ✓Selective amylin-receptor agonist — a separate pathway to GLP-1/GIP compounds
- ✓Studied as a companion to incretin research rather than a replacement for it
- ✓The newest addition to the metabolic research catalogue
- ✓Research grade - independent lab report published where we hold one
Read Carl's plain-English guide: Eloralintide on Peptide Carl ›
What is Eloralintide?
An amylin-receptor agonist. Amylin is the hormone co-secreted with insulin that signals satiety, so it sits in a different pathway to GLP-1 compounds like Retatrutide. Current research pairs the two classes rather than treating them as alternatives.
How does it compare to Cagrilintide?
Both are amylin-class. Eloralintide is the newer and more selective of the two, which is exactly why it is being studied — a cleaner receptor profile makes results easier to attribute.
When is stock available?
First batch is inbound. It is listed as sold out until it physically lands and its certificate of analysis is published — we do not sell stock we do not hold.
Eloralintide, explained
The short version: Eloralintide is Eli Lilly's amylin receptor agonist, built to be more selective than cagrilintide. A 48-week phase 2 trial reported up to 20% weight loss, and phase 3 started in late 2025.
What it is
Eloralintide (Lilly code LY3841136) is an amylin-type peptide, the same family as cagrilintide. The difference is selectivity. In Lilly's cell tests it preferred the human amylin 1 receptor, about 12 times more than the calcitonin receptor, while cagrilintide hits both. In rats it caused less taste avoidance, a lab marker linked to nausea, than cagrilintide, and it cut food intake and body weight, mostly through fat loss.
What has been studied
A phase 1 trial in 48 healthy people tested single doses. Side effects were mostly mild, and the drug's profile fitted once-weekly use.
The phase 2 trial (The Lancet, 2025) enrolled 263 adults with obesity or overweight and no type 2 diabetes at 46 US centres. After 48 weeks, average weight loss ranged from 9% at the lowest dose to 20% at the highest doses tested, against 0.4% on placebo. Nausea and fatigue were the most common side effects, and fatigue was notable, reaching over 40% in some higher-dose groups.
Lilly then launched the ENLIGHTEN phase 3 programme. ENLIGHTEN-2 (type 2 diabetes) started in December 2025 and ENLIGHTEN-1 (no diabetes) in February 2026, with further trials in sleep apnoea and knee pain.
Where the evidence stops
One phase 2 trial is the whole efficacy record so far, run by the company that makes it, in a mostly female and mostly white US group. No phase 3 results exist yet and it is not approved anywhere. The trial results belong to Lilly's material and do not describe a research vial.
Handling and storage
It arrives as a freeze-dried powder. Once bacteriostatic water goes in, it belongs in the fridge. Our reconstitution and storage guide covers the details, and the calculator does the maths.
The picky amylin agonist: strong phase 2 numbers, phase 3 only just under way.
Sources (checked 7 October 2026)
For research use only. Not for human consumption. Nothing on this page is medical advice.
Reviews from people who ordered Eloralintide
No reviews from orders with Eloralintide yet. Here is what recent customers said about ordering from us.
★★★★★
Great service as always
Nico V. · 6 Oct 2026
★★★★★
I am happy with my product
Kholofelo L. · 30 Sep 2026
★★★★
Small checkout glitch, but after following up it was quickly sorted out and everything went smoothly from there. Good customer service - thank you.
Tonia K. · 30 Sep 2026
★ 4.8 across all 16 JP Research reviews, good and bad. See them. Every reviewer gets R100 store credit, whatever they rate.
